Samsung Epis Holdings삼성에피스홀딩스

Samsung Epis Holdings reports a trailing operating loss but positive net income, and its shares are down sharply over three months.

Samsung Epis Holdings is a holding company whose main subsidiary, Samsung Bioepis, sells biosimilar drugs mostly through partners in markets including the US, Europe and Brazil. On trailing twelve-month figures to H1 2026 it had revenue of ₩251.7B and an operating loss of ₩63.6B, yet net income of ₩85.3B, and the shares closed at ₩317,500 on 26 October 2026 (market value ₩7.9T). The data does not explain what drove the gap between the operating loss and the net profit.

What stands out

• Trailing operating margin is -25.3%, while net margin is 33.9%; the data does not break down the non-operating items behind the net profit.
• Trailing free cash flow is about -₩110B, but the company holds ₩186B in cash and reports no borrowings.
• The P/E of 92.6 and P/B of 1.3 are high against the peers listed in the data (P/E of roughly 3 to 8), and ROE is only 1.4%.
• The share price is down 19% over three months and 3.8% over one month, and sits well below its 52-week high of ₩773,000 (low ₩297,500).
• Foreign ownership fell from 6.5% to 5% over the last 60 days, and foreign investors were net sellers over the last 20 days, while retail investors were net buyers.

What to watch

• The advance notice of earnings (14 October) signals a full results release, but the data does not give its date or the figures, so check the filings when they appear.
• A 21 October response to a rumour or news report and recent changes in the largest shareholder's holdings (August to October) could matter for the share price; the data does not say what the rumour was.
• The Brazil supply deal reported on 20 October is a 10-year exclusive arrangement; its financial effect is not quantified in the data.